Replimune Group (NASDAQ:REPL) Shares Down 6.9% – What’s Next?

Posted by George Bondi on Sep 12th, 2026

Shares of Replimune Group, Inc. (NASDAQ:REPL – Get Free Report) were down 6.9% on Thursday . The company traded as low as $13.43 and last traded at $13.4570. Approximately 1,392,628 shares were traded during trading, a decline of 71% from the average session volume of 4,724,739 shares. The stock had previously closed at $14.45.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the stock. JPMorgan Chase & Co. increased their target price on shares of Replimune Group from $20.00 to $21.00 and gave the company an “overweight” rating in a research report on Wednesday, August 26th. Wolfe Research raised shares of Replimune Group to an “outperform” rating in a research report on Tuesday, August 4th. Piper Sandler upgraded shares of Replimune Group from a “hold” rating to a “strong-buy” rating in a research note on Friday, July 31st. Wall Street Zen raised Replimune Group from a “strong sell” rating to a “sell” rating in a report on Saturday, May 23rd. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Replimune Group in a research report on Wednesday, August 12th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $12.00.

Check Out Our Latest Stock Report on REPL

Replimune Group Stock Down 2.4%

The business’s fifty day moving average price is $12.53 and its 200 day moving average price is $8.81. The firm has a market capitalization of $1.21 billion, a price-to-earnings ratio of -4.10 and a beta of 0.94. The company has a current ratio of 5.23, a quick ratio of 5.23 and a debt-to-equity ratio of 1.00.

Replimune Group (NASDAQ:REPL – Get Free Report) last issued its quarterly earnings results on Friday, August 14th. The company reported ($0.72) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.69) by ($0.03). On average, equities analysts expect that Replimune Group, Inc. will post -2.81 EPS for the current year.

Insider Buying and Selling

In other Replimune Group news, CFO Emily Hill sold 11,448 shares of the stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $12.97, for a total transaction of $148,480.56. Following the completion of the sale, the chief financial officer directly owned 225,108 shares of the company’s stock, valued at approximately $2,919,650.76. This trade represents a 4.84% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CAO Andrew Schwendenman sold 7,632 shares of Replimune Group stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $12.97, for a total value of $98,987.04. Following the completion of the transaction, the chief accounting officer owned 99,425 shares in the company, valued at $1,289,542.25. This trade represents a 7.13% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders sold 79,124 shares of company stock worth $1,038,364. Corporate insiders own 5.40% of the company’s stock.

Institutional Investors Weigh In On Replimune Group

Hedge funds have recently modified their holdings of the stock. BlackRock Inc. purchased a new stake in shares of Replimune Group in the second quarter valued at about $99,171,000. Balyasny Asset Management L.P. raised its holdings in Replimune Group by 507.4% during the third quarter. Balyasny Asset Management L.P. now owns 2,628,100 shares of the company’s stock worth $11,012,000 after purchasing an additional 2,195,448 shares in the last quarter. Adage Capital Partners GP L.L.C. acquired a new stake in Replimune Group in the fourth quarter valued at about $17,568,000. Commodore Capital LP purchased a new stake in Replimune Group in the 4th quarter valued at approximately $13,851,000. Finally, Opaleye Management Inc. purchased a new stake in Replimune Group in the 2nd quarter valued at approximately $15,332,000. 92.53% of the stock is owned by institutional investors and hedge funds.

Replimune Group Company Profile

(Get Free Report)

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.